Travere Therapeutics's market cap is currently ―. The company's EPS TTM is $-4.557; its P/E ratio is ―; Travere Therapeutics is scheduled to report earnings on March 3, 2025, and the estimated EPS forecast is $-0.58. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23
Income Statement	-
Total Revenue	$ 62.90M	$ 54.12M	$ 41.37M	$ 45.06M	$ 37.09M
Gross Profit	$ 61.27M	$ 52.05M	$ 39.87M	$ 40.49M	$ 35.81M
EBIT	$ -54.84M	$ -66.78M	$ -67.76M	$ -85.71M	$ -89.23M
EBITDA	$ -43.60M	$ -56.43M	$ -57.88M	$ -76.22M	$ -77.75M
Net Income Common Stockholders	$ -54.81M	$ -70.41M	$ -136.06M	$ -90.17M	$ 150.74M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 277.44M	$ 325.40M	$ 441.04M	$ 566.85M	$ 634.64M
Total Assets	$ 504.41M	$ 551.12M	$ 663.55M	$ 788.91M	$ 832.85M
Total Debt	$ 402.43M	$ 403.23M	$ 404.02M	$ 404.78M	$ 405.48M
Net Debt	$ 125.00M	$ 77.83M	$ -37.03M	$ -162.07M	$ -229.16M
Total Liabilities	$ 534.86M	$ 535.97M	$ 589.48M	$ 588.10M	$ 553.08M
Stockholders Equity	$ -30.45M	$ 15.15M	$ 74.07M	$ 200.81M	$ 279.77M
Cash Flow	-
Free Cash Flow	$ -50.70M	$ -52.24M	$ -125.47M	$ -76.00M	$ -64.06M
Operating Cash Flow	$ -42.51M	$ -40.24M	$ -119.00M	$ -70.47M	$ -59.13M
Investing Cash Flow	$ 46.13M	$ 28.61M	$ 104.90M	$ -16.95M	$ 133.32M
Financing Cash Flow	$ 46.00K	$ 782.00K	$ -525.00K	$ 124.00K	$ -634.00K

Currency in USD

Travere Therapeutics Earnings and Revenue History

Income Statement >

Travere Therapeutics Debt to Assets

Balance Sheet >

Travere Therapeutics Cash Flow

Cash Flow >

Travere Therapeutics Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing